Skip to main content
. 2016 Feb 16;7(4):351–356. doi: 10.1021/acsmedchemlett.6b00005

Figure 3.

Figure 3

In vivo efficacy of 16 versus U87 MG/M human glioblastoma xenografts. Female NCr nude mice bearing subcutaneous tumors were administered escalating doses of 16 orally as a suspension in vehicle (0.5% methylcellulose/0.2% Tween-80) or vehicle once daily (QD) for 23 days. Changes in tumor volumes over time by dose for each compound are depicted as cubic spline fits generated via Linear Mixed Effects analysis of log-transformed volumes.